[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hip-fractures\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hip-fractures":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,49,0,25,[9,57,87,112,140,172,200,226,254,282,307,330,356,383,419,445,471,496,525,551,572,594,617,641,668],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100611379","peng-block--lia-for-endoprosthesis-surgery-100611379",false,"NCT07239817","PENG Block + LIA For Endoprosthesis Surgery","PENG 360°: PENG Block + LIA Nella Endoprotesi di Anca.","PENG 360°","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form.\n* Scheduled for hip endoprosthesis surgery for femoral fracture with an anterior approach.\n* Age 18 years or older.\n* Willing and able to comply with the study protocol.\n\nExclusion Criteria:\n\n* Failure to provide informed consent.\n* Age less than 18 years.\n* Known allergy to local anesthetics or other medications used in the protocol.\n* Presence of infection at the planned injection site.\n* Pre-existing hip prosthesis or prior major surgery on the same hip (e.g., revision surgery).\n* ASA physical status class \\> IV.\n* Administration of intraoperative opiates or conversion to general anesthesia.","ALL","18 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to learn if a new local anesthesia technique can control pain as well as the standard spinal anesthesia for adults having hip endoprosthesis surgery. The main questions it aims to answer are:\n\n* Is the new local anesthesia technique as effective as standard spinal anesthesia in managing pain during the first two days after surgery?\n* Does the new technique allow participants to move their leg sooner after the operation?\n\nResearchers will compare the new local anesthesia technique (numbing medicine injected directly around the hip joint) to standard spinal anesthesia (a numbing injection in the back) to see if the new technique works just as well for pain control while possibly causing fewer side effects like nausea.\n\nParticipants who join this study will be randomly placed into one of two groups.\n\nOne group will receive the standard spinal anesthesia before their surgery.\n\nThe other group will receive the new local anesthesia technique before their surgery.\n\nAfter the operation, researchers will track the amount of extra pain medicine each participant uses and will check their ability to move their hip, knee, and foot.",[28,29,30,31,32,33],"Hip Fractures","Arthroplasty, Replacement, Hip","Pain, Postoperative","Anesthesia and Analgesia","Nerve Block","Local Anesthesia Infiltration",[35,36,37,38,39,40,41,42,43],"Pericapsular Nerve Group Block","PENG block","Local Infiltration Analgesia","Spinal Anesthesia","Hip Arthroplasty","Postoperative Pain","Femoral Fractures","Ultrasound Guidance","Early Mobilization","RECRUITING","2026-06-10",{"date":47,"type":48},"2026-06-12","ACTUAL",{"date":50,"type":48},"2025-12-09",{"date":52,"type":22},"2026-12-30",{"name":54,"class":55},"ASST Gaetano Pini-CTO","OTHER",1,{"id":58,"slug":59,"hasResults":12,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":12,"sex":18,"minAge":65,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":68,"conditions":69,"keywords":73,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":56},"100640901","validation-of-the-french-version-of-the-new-mobility-score-nms-100640901","NCT07622095","Validation of the French Version of the New Mobility Score (NMS)","Validation of the French Version of the New Mobility Score (NMS) in Hospitalized Patients With Hip Fracture","MOB-SCORE","Inclusion Criteria:\n\n* Patients aged 75 years and older admitted to a hospital department following a hip fracture and treated surgically (osteosynthesis or arthroplasty).\n* Type of fracture: pertrochanteric fracture or femoral neck fracture.\n* Sufficient proficiency in French to complete the questionnaires.\n* Patients affiliated with a health insurance scheme.\n* No objection to participate from the patient or the caregiver in case of cognitive impairment.\n\nExclusion Criteria: no exclusion criteria","75 Years",{"count":21,"type":22},"OBSERVATIONAL","The incidence of hip fractures in France is 50,000 cases per year among women and 16,000 among men, with a 1-year mortality rate of 20-24%. After a fracture, 10-30% of patients become functionally dependent. The increasing aging of the population and the rise in dependency are likely to worsen the situation of older patients in hospital settings.\n\nSeveral tools are available to assess functional independence, including the New Mobility Score (NMS), which evaluates mobility through three domains: mobility indoors, mobility outdoors, and shopping activities. The NMS has shown good performance in predicting patient mortality and functional recovery, and its use is recommended in clinical practice. However, the French version of the NMS has not yet been validated.\n\nThe French validation of the NMS is important to facilitate its implementation in clinical practice and research, particularly because of its simplicity and the need for rapid assessment tools for healthcare professionals. A French version of the NMS has been translated, and the MOB-SCORE study aims to assess its reliability and validity among healthcare professionals caring for patients with hip fractures.",[28,70,71,72],"Mobility Limitation","Independence","Autonomy",[74,75,76],"New Mobility Score","Validation","Inter-rater reliability","NOT_YET_RECRUITING","2026-05-28",{"date":80,"type":48},"2026-06-02",{"date":82,"type":22},"2026-07",{"date":84,"type":22},"2028-02",{"name":86,"class":55},"Hospices Civils de Lyon",{"id":88,"slug":89,"hasResults":12,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":12,"sex":18,"minAge":93,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100584749","cervical-myelopathy-in-hip-fracture-patients-100584749","NCT06893406","Cervical Myelopathy in Hip Fracture Patients","Inclusion Criteria:\n\n* Patient admitted to Eskenazi, Methodist, or IU North hospital for a hip fracture (femoral neck, intertrochanteric, subtrochanteric, or pertrochanteric fracture) that was caused by a ground level fall.\n\nExclusion Criteria:\n\n* Neurologic or cognitive disorder explaining the fall (dementia, Parkinson's disease, delirium, etc.)\n* Syncopal fall or fall caused by stroke or a heart condition","50 Years",{"count":95,"type":22},75,[25],"Recent evidence has demonstrated a high rate of undiagnosed cervical myelopathy in patients presenting with hip fractures from a ground level fall. Identification and treatment of cervical myelopathy can help prevent falls and future fragility fractures. The purpose of this study is to screen ground level fall hip fracture patients for cervical myelopathy using a history, physical exam, and then offer an MRI if indicated.",[99,28],"Cervical Myelopathy",[101,102],"Hip fracture","Cervical myelopathy","2026-05-26",{"date":78,"type":48},{"date":106,"type":48},"2025-05-01",{"date":108,"type":22},"2026-07-30",{"name":110,"class":55},"Indiana University",3,{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":122,"conditions":123,"keywords":124,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":56},"100598570","peng-vs-femoral-block-for-hip-fracture-analgesia-100598570","NCT07073209","PENG vs Femoral Block for Hip Fracture Analgesia","PENG vs Femoral Block for Hip Fracture, A Pragmatic Cluster-Randomized Study","Inclusion Criteria:\n\n1. Male or female ≥ 18 years of age.\n2. ASA Classification 1-4\n3. Documentation of a hip fracture diagnosis along with radiologic read indicating fracture location\n4. Written, informed consent for analgesic peripheral block placement\n\nExclusion Criteria:\n\n1. Altered mental status to the extent that it limits ability to report pain score\n2. Patient or health care proxy refusal of analgesic nerve block\n3. Allergy to study medications or contraindication to peripheral nerve block\n4. Peri-prosthetic fracture\n5. Any additional fractures in a patient with a unilateral hip fracture",{"count":120,"type":22},352,[25],"This study aims to compare the Pericapsular Nerve Group (PENG) block with femoral block for hip fracture pain. Participants presenting to the hospital with a diagnosis of hip fracture and consenting to analgesic block will receive either a PENG or femoral block. The choice of block will be dictated by a randomized monthly schedule, and all participants presenting during each four-week period will receive the designated block. A sub-group analysis will be performed to determine any difference in efficacy in participants with intracapsular versus extracapsular fractures.",[28],[125,126,127,128,129,130],"Pain","Anesthesia","Analgesia","Hip Fracture","Peripheral nerve block","Regional Anesthesia","2026-05-12",{"date":133,"type":48},"2026-05-15",{"date":135,"type":48},"2025-07-10",{"date":137,"type":22},"2027-04",{"name":139,"class":55},"Weill Medical College of Cornell University",{"id":141,"slug":142,"hasResults":12,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":12,"sex":147,"minAge":148,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":23,"phases":152,"briefSummary":153,"conditions":154,"keywords":157,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":171},"100423628","restore---study-of-agn1-loep-to-prevent-secondary-hip-fractures-100423628","NCT04796350","RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures","Randomized Controlled Study of a Local Osteo-Enhancement Procedure (LOEP) to Prevent Secondary Hip Fractures in Osteoporotic Women Undergoing Treatment of Index Hip Fractures","Inclusion Criteria:\n\n1. Subject is a postmenopausal female at least 1-year post menses and at least 65 years of age and less than 92 years of age.\n2. Subject presents with a low-energy index fragility hip fracture in one hip and will undergo surgical repair of the fractured hip.\n3. Subject has at least one of the following additional risk factors for a secondary hip fracture (as determined by subject or legally authorized representative (LAR) interview or medical record review):\n\n   * Documented falls assessment indicating subject is at moderate or high risk of falls\n   * Falls history (2 or more falls in the previous 12 months)\n   * History of vertigo, dizziness, or postural hypotension\n   * Documented T-score \\\u003C -2.5 at the hip\n   * Taking more than 3 daily prescription medications\n   * Visual impairment as confirmed by one of the following:\n\n     * Subject reports difficulty seeing\n     * Lack of depth perception or vision loss in one eye\n     * Macular degeneration\n     * Cataracts\n   * Prior non-hip fragility fracture\n   * Cognitive frailty as assessed by SPMSQ (mild cognitive impairment determined by SPMSQ ≤ to 4) or delirium\n   * Parkinson's disease stage 3 or 4\n   * 10-year hip fracture probability \\>15% using the FRAX® Fracture Risk Assessment Tool of the clinical site country\n4. Subject is expected to be ambulatory after the hip fracture repair procedure. \"Ambulatory\" is defined as a patient's ability to ambulate beyond simple transfers with or without assistive devices.\n5. Informed consent is provided by the subject or the subject's LAR. Use of an LAR to obtain patient consent requires that the patient must understand and be able to participate in post operative restrictions and requirements.\n6. The subject's willingness, ability, and commitment to participate in screening, treatment, and all follow-up evaluations for the full duration of the study has been documented.\n\nExclusion Criteria:\n\n1. Criterion omitted\n2. Criterion omitted\n3. Subject is currently enrolled in another interventional clinical study affecting the target hip.\n4. Subject has a history of hip surgery or previous hip fracture on the target unfractured hip contralateral to the index hip fracture.\n5. Subject has new fractures in addition to the index hip fracture at admission that, in the opinion of the investigator, would further compromise patient mobility, rehabilitation, or recovery.\n6. Subject has an infection at the LOEP intended treatment site or has non-intact skin or acute traumatic injuries with open wounds close to the area of intended LOEP treatment.\n7. Subject has a progressive increase in undiagnosed pain in the target hip contralateral to the index fractured hip over the previous 3 months that in the opinion of the Investigator may suggest underlying bone or joint pathology on the unfractured side.\n8. Subject has radiological evidence of gross bony or joint pathology of the hip, including signs predictive of atypical femoral fractures (e.g. cortical beaking), or has been diagnosed and\u002For treated for atypical femoral fractures.\n9. Criterion omitted\n10. Subject has a history of metabolic bone disease other than osteoporosis (e.g., Paget's disease, renal osteodystrophy, or osteomalacia).\n11. Criterion omitted\n12. Subject has active cancer\n13. Criterion omitted\n14. Criterion omitted\n15. Criterion omitted\n16. Criterion omitted\n17. Criterion omitted\n18. Subject has end stage renal insufficiency defined as an estimated glomerular filtration rate (eGFR) \\\u003C 15 mL\u002Fmin.\n19. Criterion omitted\n20. Criterion omitted\n21. Subject has moderate or severe cognitive impairment as assessed by an SPMSQ of 5 or higher.\n22. Subject has known allergies to calcium-based bone void fillers.\n23. In the judgement of the Investigator, the subject is not a good study candidate (e.g., poor mental health, or active drug or alcohol abuse issues), and or subject would not be a good candidate to undergo an ELECTIVE orthopedic surgical procedure such as a total hip arthroplasty in her current medical, physiological condition.\n24. Subject fails pre-operative or intraoperative eligibility criteria as specified in section 7.4.2. of the clinical investigation plan.","FEMALE","65 Years","91 Years",{"count":151,"type":22},2400,[25],"A randomized controlled trial to evaluate AGN1 to prevent secondary hip fractures in osteoporotic women undergoing treatment of index hip fractures. Up to 2400 subjects will be randomized between a treatment group and a control group. Subjects will be followed for a minimum of 5 years after undergoing hip fracture repair surgery.",[155,28,156],"Fragility Fracture","Osteoporosis",[156,128,155,158,159,160],"LOEP","RESTORE","Local osteo-enhancement procedure","2026-05-11",{"date":163,"type":48},"2026-05-13",{"date":165,"type":48},"2021-04-24",{"date":167,"type":22},"2029-04-01",{"name":169,"class":170},"AgNovos Healthcare, LLC","INDUSTRY",66,{"id":173,"slug":174,"hasResults":12,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":12,"sex":18,"minAge":180,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":23,"phases":183,"briefSummary":184,"conditions":185,"keywords":188,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":4},"100636565","how-tens-affects-pain-medication-use-and-muscle-function-in-older-adults-with-hip-fractures-100636565","NCT07567339","How TENS Affects Pain, Medication Use, and Muscle Function in Older Adults With Hip Fractures","Effects of Transcutaneous Electrical Nerve Stimulation (TENS) on Pain and Analgesic Use and the Association of Clinical and Psychosocial Factors With Muscle Function in Older Adults With Hip Fracture","TENS-HIP","Inclusion Criteria:\n\n* Older adults (male and female) diagnosed with hip fracture\n* Age ≥ 60 years\n* Admitted to the hospital inpatient unit (HPS)\n* Mini-Mental State Examination (MMSE) score ≥ 20\n\nExclusion Criteria:\n\n* Conditions contraindicating electrical stimulation, such as presence of a pacemaker, significant sensory loss in the lower limbs, or skin lesions at the electrode placement site\n* History of neurological or cognitive impairment that may interfere with understanding of the assessments\n* Previous treatment with neuromuscular electrical stimulation (NMES) in the lower limb within the last 3 months","60 Years",{"count":182,"type":22},32,[25],"The goal of this clinical trial is to learn if transcutaneous electrical nerve stimulation (TENS) can reduce perioperative pain in older adults with hip fractures. It will also evaluate its effects on physiological and psychological outcomes. The main questions it aims to answer are:\n\nDoes adding TENS to usual care during the preoperative phase reduce pain intensity and analgesic consumption? Does TENS affect pressure pain threshold and vital signs (blood pressure, heart rate, and respiratory rate)?\n\nResearchers will compare active TENS to sham TENS (no perceptible stimulation) to see if TENS is effective in reducing pain and improving related outcomes.\n\nParticipants will:\n\n* Undergo a standardized baseline assessment, including evaluation of pain, vital signs, anxiety, discomfort, and pressure pain threshold\n* Complete questionnaires assessing quality of life, physical activity, depressive symptoms, anxiety, fear of falling, and pain catastrophizing\n* Be randomly assigned to receive either active TENS or sham TENS\n* Receive a single 45-minute TENS session\n* Have their analgesic use recorded for the 24 hours before and after the intervention.",[28,186,187],"Femoral Neck Fractures","Intertrochanteric Femur Fracture",[28,189,190],"TENS","PAIN","2026-05-04",{"date":193,"type":48},"2026-05-08",{"date":195,"type":22},"2026-05-22",{"date":197,"type":22},"2027-01-28",{"name":199,"class":55},"University of the Sinos Valley",{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":12,"sex":18,"minAge":148,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":210,"conditions":211,"keywords":213,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":56},"100446300","translation-and-cultural-adaptation-of-the-groningen-frailty-indicator-gfi-in-patients-with-hip-fracture-100446300","NCT05091645","Translation and Cultural Adaptation of the Groningen Frailty Indicator (GFI) in Patients With Hip Fracture","Translation and Cultural Adaptation of the Greek Version of the Groningen Frailty Indicator (GFI) in Patients With Hip Fracture; a Prospective Cohort Study","Gr-GFI","Inclusion Criteria:\n\n* adult patients over 65 years old with hip fractures undergoing surgery\n* an ASA (American Society of Anesthesiologists) PS (physical status) I to III\n* non-institutionalized\n* able to communicate orally or in writing\n* consent to participate\n\nExclusion Criteria:\n\n* refused to participate\n* pathological hip fractures\n* institutionalized\n* patients with hip fracture treated conservatively\n* patients with severe cognitive dysfunction\n* patients with insufficient knowledge of the Greek language",{"count":209,"type":22},89,"This study attempts to the translation and the cultural adaptation of the Groningen Frailty Indicator (GFI) questionnaire in the Greek population in patients suffering from hip fracture.",[212,28],"Frailty Syndrome",[212,214,215,216],"Hip fractures","Cultural adaptation","Translation","2026-05-03",{"date":219,"type":48},"2026-05-07",{"date":221,"type":48},"2022-02-25",{"date":223,"type":22},"2026-11-15",{"name":225,"class":55},"University of Thessaly",{"id":227,"slug":228,"hasResults":12,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":12,"sex":18,"minAge":148,"maxAge":234,"enrollmentInfo":235,"targetDuration":4,"studyType":23,"phases":237,"briefSummary":238,"conditions":239,"keywords":241,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":56},"100429148","intramedullary-nail-versus-hip-arthroplasty-in-unstable-trochanteric-hip-fractures-100429148","NCT04868305","Intramedullary Nail Versus Hip Arthroplasty in Unstable Trochanteric Hip Fractures","Randomized Clinical Trial: Treatment of Unstable Trochanteric Hip Fractures With Intramedullary Nail Versus Hip Arthroplasty: Survival, Complications and Postoperative Patient Reported Outcomes","TUFHIPRCT","Inclusion Criteria:\n\n* Age ≥ 65 years\n* American Society of Anesthesiology Score (ASA) \\\u003C 4\n* Ambulant with or without aid (preinjury)\n* Radiological verified unstable trochanteric hip fracture (AO 31A2.2 - 3.3)\n* Written consent obtained by patient or his\u002Fher next of kin\n\nExclusion Criteria:\n\n* Previous hip surgery on ipsilateral or contralateral side\n* Non-ambulant preinjury\n* Patient not living in the area of hospital care","120 Years",{"count":236,"type":22},170,[25],"A hip fracture is a large burden to the patient with increased mortality, pain and increased need for daily assistance. Trochanteric fractures of the femur (FTF) represents about 35% of the hip fractures. Today FTFs are mainly treated with internal fixation using sliding hips screws (SHS) or intramedullary nail (IMN), whilst hip arthroplasty (THA\u002FHA) is rarely used. Despite advances in the design of the internal fixation implants there is a high failure rate, in particular in cases of FTFs classified as unstable fractures. Since the introduction of hip arthroplasty in femoral neck fractures there has been a reduction in complication rates, early mobilization and shorter hospital stays.\n\nThe primary objective of this project is to investigate if treatment with hip arthroplasty in unstable FTFs will increase the postoperative mobility, give a better general health outcome for the patient, better quality of life and reduce re-operation rate for the patients compared to those operated with the traditional IMN.",[240,28],"Hip Injuries and Disorders",[242,243],"Trochanteric hip fracture","Unstable trochanteric hip fractures","2026-04-25",{"date":246,"type":48},"2026-04-30",{"date":248,"type":48},"2021-10-12",{"date":250,"type":22},"2027-03-31",{"name":252,"class":253},"Helse Stavanger HF","OTHER_GOV",{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":23,"phases":263,"briefSummary":264,"conditions":265,"keywords":267,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":56},"100633772","posterior-pericapsular-deep-gluteal-block-combined-with-pericapsular-nerve-group-and-lateral-femoral-cutaneous-nerve-blocks-for-hip-surgery-analgesia-100633772","NCT07531030","Posterior Pericapsular Deep Gluteal Block Combined With Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blocks for Hip Surgery Analgesia","Efficacy of Combining Ultrasound-guided Posterior Pericapsular Deep Gluteal Block to Both Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blocks for Postoperative Analgesia in Orthopedic Hip Surgeries","Inclusion Criteria:\n\n* Age greater than or equal to 18 years.\n* Both genders included.\n* American Society of Anesthesiologists (ASA) physical status classification I-III.\n* Undergoing elective orthopedic hip surgery.\n* Provision of written informed consent.\n\nExclusion Criteria:\n\n* Patient refusal of procedure or participation.\n* American Society of Anesthesiologists (ASA) physical status classification IV.\n* Allergy to any of the drugs used in the study.\n* Local skin infection at the injection site.\n* Coagulation disorder.\n* History of cardiac arrhythmia, seizures, or increased intracranial tension.\n* Alcohol or drug abuse, or psychiatric disease.\n* History of chronic pain.",{"count":262,"type":22},50,[25],"This study aims to investigate the efficacy of adding a Posterior Pericapsular Deep gluteal block to two other standard nerve blocks-the Pericapsular Nerve Group block and the Lateral Femoral Cutaneous Nerve block-for patients undergoing orthopedic hip surgery. While standard blocks target the front of the hip, many patients still feel pain in the back (posterior) of the joint. Researchers will compare two groups of patients to see if this triple-block combination provides better pain relief and reduces the need for rescue opioid medications in the 24 hours following surgery.",[40,266,28],"Hip Osteoarthritis",[268,35,269,270,271,272],"Posterior Pericapsular Deep Gluteal Block","Lateral Femoral Cutaneous Nerve Block","Ultrasound-Guided Regional Anesthesia","Multimodal Analgesia","Orthopedic Hip Surgery","2026-04-18",{"date":275,"type":48},"2026-04-22",{"date":277,"type":22},"2026-06-01",{"date":279,"type":22},"2027-12-01",{"name":281,"class":55},"Ain Shams University",{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":289,"sex":18,"minAge":148,"maxAge":290,"enrollmentInfo":291,"targetDuration":4,"studyType":23,"phases":293,"briefSummary":294,"conditions":295,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":56},"100478779","effect-of-remimazolam-and-propofol-on-postoperative-delirium-100478779","NCT05514405","Effect of Remimazolam and Propofol on Postoperative Delirium","Effect of Remimazolam and Propofol on Postoperative Delirium in Elderly Patients Undergoing Hip and Knee Surgery","Inclusion Criteria:\n\n* elderly patients undergoing hip or knee arthroplasty under general anesthesia.\n* body mass index \\>30 kg\u002Fm2\n\nExclusion Criteria:\n\n* moderate to severe liver dysfunction\n* moderate to severe renal dysfunction\n* unable to extubate in the operation room after operation\n* benzodiazepine dependence\n* sensitivity to anesthetic drugs used for study (Benzodiazepines, Propofol, Remifentanil, Fentanyl citrate, Rocuronium bromide, Sugammadex, Flumazenil)\n* acute angle glaucoma\n* received (benzodiazepine, antianxiety drugs, antidepressant, antipsychotic drugs) within 24 hours.\n* acute psychotic depression\n* history stroke or cerebrovascular disease",true,"100 Years",{"count":292,"type":22},82,[25],"Remimazolam is an ultra-short acting benzodiazepine agonist which is used widely for general anesthesia and sedation. Remimazolam has several advantages. Remimazolam is rapidly metabolized by tissue esterase that it does not accumulate even after infusion for long periods of time. The presence of reversal agents (flumazenil) is also advantageous. Also, hemodynamic stability compared to propofol gives clinicians preference to use for geriatric anesthesia. However, the study on the effect of remimazolam compared to propofol on postoperative delirium have not been carried out. The purpose of the study is to compare the incidence of postoperative delirium and recovery profile in elderly patients undergoing orthopedic surgery using either remimazolam or propofol.",[28,296,297],"Knee Osteoarthritis","Femur Fracture","2026-03-24",{"date":300,"type":48},"2026-03-27",{"date":302,"type":48},"2022-08-01",{"date":304,"type":22},"2026-09-30",{"name":306,"class":55},"Inje University",{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":18,"minAge":314,"maxAge":4,"enrollmentInfo":315,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":317,"conditions":318,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":56},"100458222","metabolic-profiling-of-hematopoietic-stem-cells-in-clonal-hematopoiesis-chip-100458222","NCT05246813","Metabolic Profiling of Hematopoietic Stem Cells in Clonal Hematopoiesis (CHIP)","Metabolic Profiling of Hematopoietic Stem Cells in Clonal Hematopoiesis (CHIP): a Prospective Observational Study","Inclusion Criteria:\n\n* Age 65 years and older\n\nExclusion Criteria:\n\n* known haematological condition (myelodysplasia, leukemia, cancer)\n* inability to provide written informed consent","55 Years",{"count":316,"type":22},24,"Bone marrow samples will be collected from patients undergoing hip arthroplasty surgery. Blood and bone marrow samples will be used for metabolic profiling and analysis of relevant CHIP mutations. Combined single-cell transcriptomics and mutation-specific single-cell genotyping (biotin-PCR using mutation-targeted primers followed by sequencing) will subsequently be performed. The gene expression profile of wildtype and mutant hematopoietic stem cells will be compared, performing both broad gene set enrichment analysis and targeted analysis of metabolic pathways.",[156,319,28,320,321],"Osteoarthritis, Hip","Clonal Hematopoiesis of Indeterminate Potential","Aging",{"date":323,"type":48},"2026-03-25",{"date":325,"type":48},"2022-02-11",{"date":327,"type":22},"2030-12-31",{"name":329,"class":55},"Imelda Hospital, Bonheiden",{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":337,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":339,"conditions":340,"keywords":343,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":355},"100491987","observational-study-to-evaluate-long-term-outcome-in-hip-hemiarthroplasty-100491987","NCT05686278","Observational Study to Evaluate Long-Term Outcome in Hip Hemiarthroplasty","A Post-market Clinical Follow-up (PMCF) Study to Evaluate Clinical, Radiographic and Patient Reported Outcomes Following a Hip Hemiarthroplasty Surgery Using Corin Devices","Inclusion Criteria:\n\n1. Both genders.\n2. Adult subjects.\n3. Subjects clinically suitable for a hip hemiarthroplasty surgery with Corin hip devices based on physical examination, medical history and diagnosis such as: non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis in which the acetabulum does not require replacement, treatment of non-union, femoral neck and trochanteric fractures of the proximal femur, revision of failed partial hip replacements in which the acetabulum does not require replacement.\n4. The subject is willing to comply with the required follow-up visits as per protocol.\n5. The subject, or a designated trusted person in case the subject is unable to do, has signed a Patient Informed Consent Form (PICF), specific to this study, and approved by the local EC.\n\nExclusion Criteria:\n\n1. Subjects with active infection or sepsis or osteomyelitis.\n2. Subjects with unsuitable or insufficient bone support preventing proper fixation of the prosthesis.\n3. Subject with marked bone loss or bone absorption.\n4. Subject with metabolic disorders which may impair bone formation or bone quality.\n5. Subjects under guardianship.\n6. Subjects under jusicial protection\n7. Subjects in the opinion of the Investigator\u002F investigative team who will be unable to comply with study procedures (Examples: recent psychotic or mania disorders, alcohol, drug or substance abusers) and\u002For those unable for any medical or other reason to comply with study procedures\u002Fvisits.",{"count":338,"type":22},368,"This PMCF study is designed to collect safety and efficacy data on hip hemiarthroplasty surgeries with Corin BiPolar-i shell and the Oceane+ or Meije Duo femoral stem up to 10 years.",[28,341,319,342,186],"Hip Hemiarthroplasty","Avascular Necrosis of Hip",[344,345,28],"Hemiarthroplasty","Acetabulum","2026-03-17",{"date":348,"type":48},"2026-03-18",{"date":350,"type":48},"2023-06-29",{"date":352,"type":22},"2035-09",{"name":354,"class":170},"Corin",4,{"id":357,"slug":358,"hasResults":12,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":362,"eligibilityCriteria":363,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":180,"enrollmentInfo":364,"targetDuration":4,"studyType":23,"phases":366,"briefSummary":368,"conditions":369,"keywords":371,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":56},"100559575","phase-4-bupivacaine-liposome-plus-bupivacaine-or-ropivacaine-for-pericapsular-nerve-group-block-in-hip-arthroplasty-peng-100559575","NCT06565910","Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for Pericapsular Nerve Group Block in Hip Arthroplasty (PENG)","Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for PENG Block on Post Operative Pain Management in Patients Undergoing Hip Arthroplasty: a Prospective, Randomized, Single Blind, Active Controlled Study","PENG","Inclusion Criteria:\n\n* American Society of Anesthesiologists(ASA) I\\~II\n* Normal coagulation\n* Clinical diagnosis of hip fracture\n\nExclusion Criteria:\n\n* Presence of severe systemic diseases or ASA grade III or higher\n* Allergy to amide local anesthetics",{"count":365,"type":22},60,[367],"PHASE4","The goal of this clinical trial is to study the analgesic effect of liposomal bupivacaine plus bupivacaine for Pericapsular Nerve Group (PENG) block in postoperative pain management following hip replacement surgery. It will also assess the safety of liposomal bupivacaine for this purpose. The main questions it aims to answer are:\n\n1. Is liposomal bupivacaine plus bupivacaine superior to ropivacaine in terms of analgesic efficacy, duration of pain relief, opioid consumption, and patient satisfaction?\n2. What medical problems do participants encounter when using liposomal bupivacaine plus bupivacaine for PENG block in postoperative pain management following hip replacement surgery?\n\nResearchers will compare liposomal bupivacaine plus bupivacaine to ropivacaine (a routinely used regional anesthetic in clinical practice) to determine if liposomal bupivacaine plus bupivacaine is more effective for pain management following hip replacement surgery.\n\nParticipants will:\n\n1. Receive liposomal bupivacaine plus bupivacaine or ropivacaine as a regional anesthetic for PENG block under ultrasound guidance.\n2. Undergo hip replacement surgery under spinal anesthesia.\n3. Have pain relief, opioid analgesic consumption, and incidence of complications assessed at multiple time points within 72 hours after surgery.",[186,370,28],"Femur Head Necrosis",[372,36,39,373],"Bupivacaine Liposome","Randomized Controlled Trial","2026-03-11",{"date":376,"type":48},"2026-03-13",{"date":378,"type":48},"2024-12-04",{"date":380,"type":22},"2026-07-01",{"name":382,"class":55},"Huazhong University of Science and Technology",{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":12,"sex":18,"minAge":93,"maxAge":4,"enrollmentInfo":390,"targetDuration":4,"studyType":23,"phases":392,"briefSummary":393,"conditions":394,"keywords":397,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":418},"100549791","evaluating-a-strategy-to-improve-pre-anesthesia-care-discussions-my-anesthesia-choice-hip-fracture-100549791","NCT06438640","Evaluating a Strategy to Improve Pre-Anesthesia Care Discussions (My Anesthesia Choice-Hip Fracture)","Implementation and Evaluation of a Strategy to Improve Pre-Anesthesia Care Discussions (My Anesthesia Choice-Hip Fracture)","Inclusion:\n\nAge 50 and older Planned surgery to treat a hip fracture\n\nExclusion:\n\nContraindication to spinal anesthesia: current anticoagulant therapy or coagulopathy Contraindication to spinal anesthesia: critical aortic stenosis Contraindication to spinal anesthesia: skin infection over the lumbar spine",{"count":391,"type":22},1881,[25],"The objective of this study is to assess the implementation process for and the effectiveness of a quality improvement (QI) strategy to increase shared decision-making around anesthesia options for hip fracture surgery at 6 US hospitals. The QI strategy is to be facilitated by a clinician-administered 1-page bedside conversation aid designed to improve the quality of physician-patient communication, paired with brief clinician training. The evaluation will occur via a stepped wedge, cluster randomized trial to be carried out over a period of 34 months.",[28,186,395,396],"Intertrochanteric Fractures","Subtrochanteric Fractures",[398,399,400,401,402,403,404,405,406,407,408],"hip fracture","femoral neck","intertrochanteric","subtrochanteric","fracture","anesthesia","observational study","survey","shared decision making","My Anesthesia Choice","MAC-HF","2026-03-09",{"date":411,"type":48},"2026-03-12",{"date":413,"type":48},"2024-08-15",{"date":415,"type":22},"2028-06-15",{"name":417,"class":55},"University of Pennsylvania",6,{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":18,"minAge":148,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":23,"phases":428,"briefSummary":429,"conditions":430,"keywords":431,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":56},"100626215","one-versus-two-doses-of-tranexamic-acid-in-surgically-treated-extracapsular-hip-fractures-100626215","NCT07432737","One Versus Two Doses of Tranexamic Acid in Surgically Treated Extracapsular Hip Fractures","Prophylactic Administration of One Versus Two Doses of Tranexamic Acid in Surgically Treated Patients With Pertrochanteric and Subtrochanteric Femoral Fractures","Inclusion Criteria:\n\n* Written informed consent obtained\n* Patients aged 65 years or older\n* Patients with pertrochanteric femoral fracture (AO\u002FOTA classification: 31A1.2, 31A1.3, 31A2, 31A3) or subtrochanteric femoral fracture (AO\u002FOTA classification: 32; fractures from the level of the lesser trochanter to 5 cm distally)\n* Surgical treatment performed within 48 hours of hospital admission\n\nExclusion Criteria:\n\n* Age younger than 65 years\n* Known allergy or hypersensitivity to tranexamic acid\n* Active thromboembolic event (deep vein thrombosis, arterial thrombosis, pulmonary embolism) or history of vascular event within the past year (myocardial infarction, coronary or peripheral vascular stenting, thromboembolism, stroke)\n* Impaired renal function defined as serum creatinine \\>120 µmol\u002FL in the last preoperative laboratory test\n* History of malignant disease\n* History of seizure disorder or chronic anticonvulsant therapy\n* Polytrauma or multiple trauma\n* More than one fracture\n* Previous fracture of the same hip\n* Preoperative hemoglobin level \\\u003C8 g\u002FdL (last laboratory test before surgery)\n* Thrombocytopenia or other coagulation disorders\n* Treatment with vitamin K antagonists with INR \\>1.5\n* Treatment with low-molecular-weight heparins without appropriate preoperative discontinuation according to clinical protocol (usually ≥24 hours for prophylactic doses and ≥24-36 hours for therapeutic doses)\n* Treatment with direct oral anticoagulants without appropriate preoperative discontinuation (usually 24-48 hours, depending on renal function and bleeding risk)\n* Treatment with P2Y12 inhibitors (e.g., ticagrelor, clopidogrel, prasugrel) when, according to anesthesiologist assessment, surgery cannot be safely performed within 48 hours",{"count":427,"type":22},120,[25],"The goal of this clinical trial is to learn whether giving one dose or two doses of tranexamic acid can safely lower blood loss in older adults having surgery for certain hip fractures. The study includes adults aged 65 years or older who need surgery for pertrochanteric or subtrochanteric hip fractures.\n\nThe main questions the study aims to answer are:\n\n* Does giving two doses of tranexamic acid lower the need for blood transfusions compared to one dose?\n* Does tranexamic acid help keep hemoglobin levels higher after surgery?\n* Is tranexamic acid safe in this group of participants? Researchers will compare participants who receive one dose of tranexamic acid with those who receive two doses to see which approach works better and is safe.\n\nParticipants will:\n\n* Receive either one dose of tranexamic acid before surgery or two doses, one before and one after surgery\n* Have standard surgery to fix their hip fracture within 48 hours of hospital admission\n* Be monitored during their hospital stay for blood loss, transfusions, and medical problems\n* Be followed for up to 90 days after surgery to check for safety A total of 120 participants will take part in this study, which is being conducted at the University Clinic \"St. Naum Ohridski\" in Skopje, North Macedonia.",[28],[432,433,434,435],"tranexamic acid","blood loss","blood transfusion","safety","2026-02-24",{"date":438,"type":48},"2026-02-27",{"date":440,"type":48},"2026-02-17",{"date":442,"type":22},"2027-09",{"name":444,"class":55},"University Hospital for Surgical Diseases St. Naum Ohridsk i- Skopje",{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":12,"sex":18,"minAge":180,"maxAge":234,"enrollmentInfo":452,"targetDuration":4,"studyType":23,"phases":454,"briefSummary":455,"conditions":456,"keywords":457,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":468,"locationsCount":470},"100625219","precision-care-for-older-persons-100625219","NCT07419789","Precision Care for Older Persons","Precision Care for Older Persons With Hip Fractures","Inclusion Criteria:\n\n1. ≥ 60 years old,\n2. had been transferred from the emergency department to the hospital due to a unilateral hip fracture,\n3. repair of the hip fracture involved either hip arthroplasty or internal fixation, 4) their primary place of residence was northern Taiwan\n\nExclusion Criteria:\n\n1. severity of cognitive impairment (a CMMSE score of \\\u003C 10),\n2. known to be terminally ill,\n3. has no primary family caregiver,\n4. residing in an institutional care facility",{"count":453,"type":22},218,[25],"This study aims to 1) develop an Advanced Person-Centered (APC) Smart Home Care Model that is able to predict patient outcomes; and 2) evaluate the effectiveness of this model by assessing improvements in care and recovery for older individuals post hip fracture.",[28],[398,458,459,460,461],"family caregiving","smart care","person-centered care","precision care","2026-02-11",{"date":464,"type":48},"2026-02-19",{"date":466,"type":22},"2026-08-01",{"date":327,"type":22},{"name":469,"class":55},"Chang Gung Memorial Hospital",2,{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":4,"eligibilityCriteria":477,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":148,"enrollmentInfo":478,"targetDuration":4,"studyType":23,"phases":479,"briefSummary":480,"conditions":481,"keywords":483,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":355},"100556175","evaluation-of-fracture-migration-after-internal-fixation-of-femoral-neck-fractures-in-younger-adults-a-clinical-rct-using-rsa-100556175","NCT06521671","Evaluation of Fracture Migration After Internal Fixation of Femoral Neck Fractures in Younger Adults: A Clinical RCT Using RSA","Evaluation of Femoral Neck Fracture Migration After Internal Fixation With an Angle Stable Implant Compared With Gold Standard Cannulated Cancellous Screws in Young Adults: Study Protocol for a Clinical RCT Using Radiostereometric Analysis","Inclusion Criteria:\n\n* Femoral neck fracture (DS720)\n* Age 18-64 years\n* Ability to speak and read Danish\n* Willingness to participate\n\nExclusion Criteria:\n\n* Pathological, basicervical or transcervical fracture\n* Clinical Frailty Scale ≥5, indicating mild to severe frailty prior to the fracture\n* Cognitive impairment that hinders informed consent\n* Previous fracture in the ipsilateral femur\n* Patients who are unwilling or incapable of following post-operative care instructions.\n* Comorbidities making the participant ineligible for internal fixation such as:\n\n  * Material sensitivity, documented or suspected\n  * Active or suspected latent infection, sepsis or marked local inflammation in or around the surgical area\n  * Compromised vascularity, inadequate skin or neurovascular status\n  * Compromised bone stock that cannot provide adequate support and\u002For fixation of the device due to disease, infection or prior implantation\n  * Other physical, mental, medical or surgical conditions that would preclude the potential benefit of surgery.",{"count":95,"type":22},[25],"The goal of the clinical trial is to compare different surgical methods for internal fixation of femoral neck fractures in younger adults.\n\nThe main question it aims to answer is:\n\nIs internal fixation with the novel implant consisting of three angle stable screws locked together by a plate equal to internal fixation with cancellous screws or a sliding hip screw in younger adults under 65 years of age in terms of fracture migration?\n\nThe study will examine how stable the fracture remains during healing. This will be measured by assessing how much the fracture moves after surgery using a highly precise imaging method called radiostereometric analysis (RSA). The study will also record complications and evaluate pain, health related quality of life, and hip function over time.\n\nThe participants will be treated with either a novel angle stable implant (Dynaloc), cannulated cancellous screws or sliding hip screw and followed up at 6 weeks, 12 weeks, 6 months and 12 months. Recruitment will continue until 75 participants, 25 in each group, have completed the 12-week follow-up for the primary outcome.",[186,482,28],"Internal Fixation; Complications",[484,485,398,486],"femoral neck fracture","radiostereometric analysis","internal fixation","2026-01-24",{"date":489,"type":48},"2026-01-27",{"date":491,"type":48},"2025-06-16",{"date":493,"type":22},"2028-12",{"name":495,"class":55},"Odense University Hospital",{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":502,"eligibilityCriteria":503,"healthyVolunteers":12,"sex":18,"minAge":93,"maxAge":4,"enrollmentInfo":504,"targetDuration":4,"studyType":23,"phases":506,"briefSummary":507,"conditions":508,"keywords":510,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":470},"100620490","phase-4-haemodynamic-effects-and-complications-of-continuous-versus-single-shot-spinal-anaesthesia-for-hip-fracture-surgery-100620490","NCT07358299","Haemodynamic Effects and Complications of Continuous Versus Single-shot Spinal Anaesthesia for HIP Fracture Surgery","A Comparison of Haemodynamic Effects, as Assessed by Cardiac Output Monitoring, and Complications of Continuous Versus Single-Shot Spinal Anaesthesia for Hip-Fracture Surgery in Patients Over 50 Years of Age","CHIPS","Inclusion Criteria:\n\n* Age \\> 50 years, regardless of gender\n* Diagnosis of a proximal femur fracture\n* Orthopedic qualification for open reduction and internal fixation of the fracture\n* Informed consent for the surgical procedure\n* Informed consent for regional anesthesia, i.e., a central neuraxial block (spinal anesthesia)\n* Informed consent to participate in the study\n\nExclusion Criteria:\n\n* Age \\\u003C 50 years, regardless of gender\n* Refusal to consent to surgical treatment\n* Refusal to consent to regional anesthesia\n* Refusal to consent to participate in the study\n* Inability to provide informed consent\n* Allergy to local anesthetic agents\n* Severe congenital or acquired coagulation disorders\n* Failure to meet the recommended time interval between the last dose of an anticoagulant and central neuraxial blockade, according to the 2022 European Journal of Anaesthesiology (EJA) guidelines\n* Infection at the block site or a systemic infection (i.e., sepsis, septic shock)\n* Patients with multiple organ dysfunction syndrome requiring hospitalization in the Intensive Care Unit for stabilization of vital functions\n* Clinical signs of increased intracranial pressure or suspicion of an intracranial mass on imaging studies\n* Other contraindications to spinal anesthesia as judged by the qualifying physician",{"count":505,"type":22},216,[367],"This research project aims to identify a safer method of spinal anaesthesia for elderly patients undergoing surgical stabilisation of proximal femoral fractures.\n\nThe study's primary objective is to compare two spinal anaesthesia techniques: the continuous method (investigational), which allows titration of local anaesthetic doses through a catheter placed in the subarachnoid space, and the conventional single-shot bolus injection.\n\nThe main hypothesis is that the continuous catheter technique reduces the incidence of intraoperative hypotension and related complications, such as delirium, acute kidney injury, and cardiovascular events.\n\nBeyond haemodynamic stability-assessed through advanced continuous monitoring of cardiac output and vascular resistance-the study will evaluate early and late complications, as well as quality of life up to 24 months post-surgery.\n\nThe project is a prospective, randomised, multicentre clinical trial including at least 216 patients over 50 years of age, randomly assigned to one of the two groups.\n\nProximal femoral fractures are a major and growing global health issue, particularly among geriatric patients with multiple comorbidities. The conventional single-shot spinal anaesthesia, though widely used, carries a high risk of hypotension, potentially leading to delirium, acute kidney injury, stroke, and cardiac events. These complications worsen prognosis, decrease quality of life, and increase mortality.\n\nMost existing studies are over two decades old, based on small cohorts and outdated anaesthetic protocols, and lack long-term follow-up data (\\>30 days) on neurological outcomes, functional recovery, quality of life, and mortality. Moreover, no modern trials have provided direct, comprehensive comparisons between single-shot and continuous spinal anaesthesia.\n\nThis project therefore seeks to fill this critical evidence gap through a robust randomised clinical trial. Using precise, continuous measurements of arterial pressure, vascular resistance, and cardiac output, alongside long-term assessments of neurological outcomes, quality of life, and survival, it aims to determine whether continuous spinal anaesthesia offers superior safety and should become the new standard of care for this vulnerable population.",[509,28],"Anesthesia, Spinal",[511,512,513,514,515],"Continuous spinal anaesthesia","Late side effects of spinal anaesthesia","Haemodynamic stability","Follow-up care after proximal femoral fractures","Quality of life after proximal femoral fractures","2026-01-21",{"date":518,"type":48},"2026-01-23",{"date":520,"type":22},"2026-01-15",{"date":522,"type":22},"2029-11-01",{"name":524,"class":55},"Centre of Postgraduate Medical Education",{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":531,"eligibilityCriteria":532,"healthyVolunteers":12,"sex":18,"minAge":180,"maxAge":234,"enrollmentInfo":533,"targetDuration":4,"studyType":23,"phases":535,"briefSummary":536,"conditions":537,"keywords":539,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":546,"completionDateStruct":547,"leadSponsor":549,"locationsCount":4},"100588129","delivery-and-implementation-of-a-randomised-crossover-trial-on-thrombosis-100588129","NCT06937372","Delivery and Implementation of a Randomised Crossover Trial on Thrombosis","Delivery and Implementation of a Randomised Cluster Crossover Trial on Thrombosis","DIRECT","Inclusion Criteria:\n\n* Adults from 60 to 150 years sustaining fragility hip fracture identified by their entry into UK hip registries.\n\nExclusion Criteria:\n\n* Individuals who do not meet the eligibility criteria to be enrolled in the NHFD and SHFA registries Hip fracture individuals above 150 years of age.",{"count":534,"type":22},21194,[25],"What is the Study About? The DIRECT study (Delivery and Implementation of a Randomised Crossover Trial on Thrombosis) is a large research project investigating the best way to prevent blood clots (thrombosis) in people who break their hip. The study will compare two common treatments: aspirin (a tablet) and low molecular weight heparin (LMWH, an injection).\n\nEvery year, thousands of people in the UK suffer a hip fracture, which often requires surgery and hospital care. After a hip fracture, patients are at risk of developing serious blood clots in their legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE), which can be life-threatening. Currently, doctors prescribe different medications to prevent these clots, but there is uncertainty about which treatment is best for people with hip fractures.\n\nWhy is This Study Needed? Blood clot prevention is vital for hip fracture patients, but the current recommended treatment (LMWH) involves daily injections for 28 days, which some patients find uncomfortable and difficult to manage at home. Aspirin, a tablet taken by mouth, is a much simpler alternative, but there is not enough evidence to confirm whether it is as effective and safe as LMWH in this group of patients.\n\nThe DIRECT study will help doctors and the NHS understand whether aspirin could be a safe and cost-effective alternative to LMWH. If aspirin is found to be just as effective, it could make treatment easier for patients and save millions of pounds for the NHS.\n\nHow Will the Study Work? The study will involve 96 hospitals across the UK and will include over 21,000 patients aged 60 and older who have broken their hip. Hospitals will be randomly assigned to use either aspirin or LMWH as their standard treatment for a set period. After this, they will switch to the other treatment. This approach allows researchers to compare the two treatments fairly.\n\nAll data will be collected from national NHS databases, which routinely record patient care and outcomes. This means patients will not need to do anything extra or attend additional follow-ups.\n\nWhat Are the Expected Benefits?\n\nThis study will provide clear evidence on which treatment is better for preventing blood clots while minimising risks like bleeding. If aspirin is shown to be as effective as LMWH, it could:\n\n* Reduce the need for daily injections, making treatment more comfortable for patients.\n* Lower NHS costs, as aspirin is much cheaper than LMWH.\n* Provide a simple, widely available treatment option for older adults with hip fractures.\n\nHow Will Patient Data Be Protected? The study will use anonymised patient data from NHS records. This means that all personal details will be kept confidential and protected according to strict NHS and research regulations. Patients who do not want their data to be used can opt out via NHS data-sharing policies.\n\nSummary The DIRECT study is an important project that will help improve care for hip fracture patients by determining whether aspirin can be a safe and effective alternative to injections for preventing blood clots. The results will help shape future NHS guidelines, ensuring patients receive the best possible treatment while reducing unnecessary costs and discomfort.",[28,538],"Venous Thromboembolism (VTE)",[101,540,541,542],"Blood clot","Aspirin","Low molecular weight heparin (LMWH)","2026-01-05",{"date":545,"type":48},"2026-01-06",{"date":466,"type":22},{"date":548,"type":22},"2028-04-30",{"name":550,"class":55},"Queen Mary University of London",{"id":552,"slug":553,"hasResults":12,"nctId":554,"briefTitle":555,"officialTitle":556,"acronym":4,"eligibilityCriteria":557,"healthyVolunteers":12,"sex":18,"minAge":148,"maxAge":4,"enrollmentInfo":558,"targetDuration":4,"studyType":23,"phases":560,"briefSummary":561,"conditions":562,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":56},"100593152","effects-of-esketamine-combined-with-dexmedetomidine-on-postoperative-sleep-quality-100593152","NCT07002723","Effects of Esketamine Combined With Dexmedetomidine on Postoperative Sleep Quality","Effects of Esketamine Combined With Dexmedetomidine on Postoperative Sleep Quality in Elderly Patients Undergoing Hip Surgery:A Superiority Randomized Controlled Trail","Inclusion Criteria:\n\n* Age≥ 65 years old;\n* Hip fracture surgery under neuraxial anesthesia;\n* Signed informed consent.\n\nExclusion Criteria:\n\n* ASA classification≥ Class V;\n* Presence of neuraxial anesthesia contraindications: coagulation dysfunction, thrombocytopenia, neuraxial mass, puncture site infection, etc.;\n* Patients with contraindications to esketamine (such as allergies, intracranial aneurysms, hyperthyroidism and glaucoma);\n* Patients with contraindications to dexmedetomidine (allergies);\n* Patients with severe cardiovascular diseases such as sick sinus syndrome, severe sinus bradycardia (heart rate \\\u003C 50 beats\u002Fmin), atrioventricular block grade II or above without pacemaker, unstable angina, severe valvular heart disease, severe arrhythmia, severe macrovascular disease with New York Heart Association class III patients, etc.;\n* Obstructive sleep apnea syndrome (STOP-BANG score \\> 3 points);\n* Patients with severe hepatic and renal insufficiency (such as Child-Pugh score III, creatinine clearance \\\u003C 35 mL\u002Fmin, preoperative dialysis);\n* Those who have delirium, dementia, moderate to severe cognitive dysfunction and psychiatric disorders before the start of the trial and are unable to communicate and cooperate with the investigator.",{"count":559,"type":22},96,[25],"1. Eligible patients are randomly divided into experimental and control groups；\n2. The experimental group is given esketamine combined with dexmedetomidine，while the control group is given normal saline；\n3. The patients' sleep, pain, and cognition are followed up after surgery.",[28],"2025-11-30",{"date":565,"type":48},"2025-12-05",{"date":567,"type":48},"2025-06-20",{"date":569,"type":22},"2026-06-30",{"name":571,"class":55},"Peking University Shenzhen Hospital",{"id":573,"slug":574,"hasResults":12,"nctId":575,"briefTitle":576,"officialTitle":576,"acronym":4,"eligibilityCriteria":577,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":578,"enrollmentInfo":579,"targetDuration":4,"studyType":23,"phases":581,"briefSummary":582,"conditions":583,"keywords":584,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":56},"100537527","phase-4-comparison-of-cryoablation-of-pericapsular-nerve-group-peng-to-fascia-iliaca-catheter-in-patients-with-a-hip-fracture-100537527","NCT06278987","Comparison of Cryoablation of Pericapsular Nerve Group (PENG) to Fascia Iliaca Catheter in Patients With a Hip Fracture","Inclusion Criteria:\n\n* Patients undergoing hip fracture repair aged 18-85.\n\nExclusion Criteria:\n\n* Patients who have an exclusion to regional anesthesia.\n* Patients who are pregnant assessed via self-report or pregnancy test if they have taken one.\n* Non-English speakers\n* Patients who already had their fracture repaired\"","85 Years",{"count":580,"type":22},150,[367],"The purpose of this study is to determine if patients with hip fractures who undergo cryoablation of the PENG have improved pain control 30 days from surgery when compared to those who have a fascia iliaca catheter.",[28],[214],"2025-11-24",{"date":587,"type":48},"2025-11-25",{"date":589,"type":48},"2024-10-01",{"date":591,"type":22},"2027-10-01",{"name":593,"class":55},"University of Minnesota",{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":599,"acronym":4,"eligibilityCriteria":600,"healthyVolunteers":12,"sex":18,"minAge":601,"maxAge":578,"enrollmentInfo":602,"targetDuration":4,"studyType":23,"phases":604,"briefSummary":605,"conditions":606,"keywords":607,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":615,"locationsCount":470},"100530189","effects-of-pericapsular-nerve-group-block-applied-in-patients-undergoing-hip-fracture-surgery-100530189","NCT06183541","Effects of Pericapsular Nerve Group Block Applied in Patients Undergoing Hip Fracture Surgery.","Effects of Pericapsular Nerve Group (PENG) Block Applied for Analgesia on the Postoperative Process in Patients Undergoing Hip Fracture Surgery.","Inclusion Criteria:\n\n* Patients who will undergo hip fracture surgery Women and men aged 30-85\n\nExclusion Criteria:\n\n* Patients under 30 years old, over 85 years old\n* American Society of Anesthesiology (ASA) IV,\n* Those with cognitive impairment (alzheimer, dementia, delirium, etc.)\n* Those with application site infection\n* Those who are allergic to local anesthetic substances\n* Patients are non-consenting patients.","30 Years",{"count":603,"type":22},70,[25],"In this study, it was aimed to compare the multimodal analgesia application or the pericapsular nerve group (PENG) block methods in patients undergoing hip surgery. The effectiveness and benefit rate of the PENG block in postoperative pain will be evaluated.\n\nPostoperative pain, need for additional analgesia, range of motion of the hip joint, mobilization time, length of hospital time and adverse events in patients undergoing hip fracture surgery with and without PENG block will be investigated.",[28,30],[36,126],"2025-11-16",{"date":610,"type":48},"2025-11-19",{"date":612,"type":48},"2023-11-21",{"date":614,"type":22},"2026-01-30",{"name":616,"class":253},"Umraniye Education and Research Hospital",{"id":618,"slug":619,"hasResults":12,"nctId":620,"briefTitle":621,"officialTitle":622,"acronym":623,"eligibilityCriteria":624,"healthyVolunteers":12,"sex":18,"minAge":625,"maxAge":4,"enrollmentInfo":626,"targetDuration":4,"studyType":23,"phases":628,"briefSummary":629,"conditions":630,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":632,"lastUpdatePostDateStruct":633,"startDateStruct":635,"completionDateStruct":637,"leadSponsor":639,"locationsCount":603},"100419595","hip-fracture-accelerated-surgical-treatment-and-care-track-2-trial-100419595","NCT04743765","HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial","HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 (HIP ATTACK-2) Trial","HIP ATTACK-2","Inclusion Criteria:\n\n1. age ≥45 years;\n2. diagnosis of hip fracture during working hours with a low-energy mechanism requiring surgery;\n3. troponin elevation ( at least one troponin measurement above the upper limit of normal occurring from the time of hip fracture to the time of randomization); and\n4. informed consent.\n\nExclusion Criteria:\n\n1. taking a therapeutic dose of an anticoagulant for which no reversing agent is available and the anesthesiologist or surgeon believe surgery within 6 hours of eligibility criteria met would not be safe;\n2. patients on a therapeutic vitamin K antagonist with a history of heparin induced thrombocytopenia (HIT);\n3. patients with peri-prosthetic fracture, open fracture or bilateral fractures;\n4. patients requiring an emergency surgery for another reason (e.g., subdural hematoma);\n5. patients with acute myocardial infarction deemed to be clinically unstable, with a mechanical complication (i.e., acute papillary muscle rupture, ventricular septal defect), ST elevation myocardial infarction, or cardiogenic shock;\n6. patients refusing consent; or\n7. patients previously enrolled in HIP ATTACK-2.","45 Years",{"count":627,"type":22},1100,[25],"The HIP ATTACK-2 trial is a multicentre, international, parallel group randomized controlled trial to determine whether accelerated surgery for hip fracture in patients with acute myocardial injury is superior to standard care in reducing death at 90 days after randomization. The trial will also assess secondary outcomes at 90 days after randomization: inability to independently walk 3 metres, time to first mobilization (first standing and first full weight bear), composite and individual assessment of major complications (e.g., mortality, non-fatal myocardial infarction, acute congestive heart failure, and stroke), delirium, length of stay, pain, and quality of life.",[28,631],"Myocardial Injury","2025-09-25",{"date":634,"type":48},"2025-10-01",{"date":636,"type":48},"2021-11-22",{"date":638,"type":22},"2027-05-31",{"name":640,"class":55},"Population Health Research Institute",{"id":642,"slug":643,"hasResults":12,"nctId":644,"briefTitle":645,"officialTitle":646,"acronym":4,"eligibilityCriteria":647,"healthyVolunteers":12,"sex":18,"minAge":148,"maxAge":4,"enrollmentInfo":648,"targetDuration":4,"studyType":23,"phases":650,"briefSummary":651,"conditions":652,"keywords":654,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":659,"lastUpdatePostDateStruct":660,"startDateStruct":662,"completionDateStruct":664,"leadSponsor":666,"locationsCount":56},"100548794","spinal-versus-general-anesthesia-on-postoperative-pulmonary-complications-100548794","NCT06425627","Spinal Versus General Anesthesia on Postoperative Pulmonary Complications","Spinal Versus General Anesthesia on Postoperative Pulmonary Complications in Elderly Patients With Delayed Operation of Hip Fracture","Inclusion Criteria:\n\n* Patients ≥ 65 years old\n* ASA Class I \\~ III\n* Surgical repair of femoral neck, intertrochanteric or subtrochanteric fractures\n* The time from diagnosis to surgery is more than 48 hours\n\nExclusion Criteria:\n\n* Unable to walk about 3 meters or across a room without assistance before the fracture\n* Emergency surgery\n* Congestive heart failure, asthma, anemia (Hb \\\u003C 90 g\u002FL), hypoalbuminemia (ALB \\\u003C 35g\u002FL)\n* Abnormal coagulation function\n* Severe aortic stenosis\n* Injection site infection or increased intracranial pressure\n* Patients have participated in previous trials or have been determined by a surgeon or anesthesiologist to be unsuitable for randomization\n* The written informed consent of the patient or his\u002Fher representative cannot be obtained",{"count":649,"type":22},40,[25],"The objective of this study was to investigate the difference in postoperative pulmonary complications (PPCs) between spinal anesthesia and general anesthesia in patients undergoing delayed hip surgery.",[653,126,28],"Pulmonary Complication",[101,655,656,657,658],"delayed surgery","pulmonary complication","spinal anesthesia","general anesthesia","2025-09-11",{"date":661,"type":48},"2025-09-17",{"date":663,"type":48},"2024-06-12",{"date":665,"type":22},"2026-05-20",{"name":667,"class":55},"Tongji Hospital",{"id":669,"slug":670,"hasResults":12,"nctId":671,"briefTitle":672,"officialTitle":673,"acronym":4,"eligibilityCriteria":674,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":675,"targetDuration":4,"studyType":23,"phases":676,"briefSummary":677,"conditions":678,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":681,"lastUpdatePostDateStruct":682,"startDateStruct":684,"completionDateStruct":686,"leadSponsor":687,"locationsCount":56},"100547396","evaluating-the-efficacy-of-a-mobile-application-in-postoperative-rehabilitation-100547396","NCT06407427","Evaluating the Efficacy of a Mobile Application in Postoperative Rehabilitation","Using a Mobile Application for In-Bed Conditioning Exercises for Orthopedic Postoperative Patients","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* English reading\u002Fspeaking\n* Are status post low-energy hip fracture, total knee\u002Fhip arthroplasty, or single to multilevel spinal fusion without paralysis\n* Must be able bodied enough to participate in a mobile app tool for physical therapy\n* Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration\\]\n\nExclusion Criteria:\n\n* Severe cognitive impairment: Not alert and oriented to person, place, time, and reason for being the hospital; and unable to follow 2 step commands\n* Severe physical impairment:\n\n  * Neurologic paralysis\n  * Polytraumas with restrictions incompatible with anti-gravity exercises\n  * Knee immobilization, bed rest\n* Unstable medical conditions:\n\n  * On ventilatory support\n  * Utilizing high degrees of oxygen support (continuous BiPAP, high flow nasal cannula, nonrebreather mask, aerosol mask \\>3L\u002Fmin)\n  * Hemodynamic instability requiring pressor medication support (can include those on pressors for elevated mean arterial pressure goals (MAPs))\n  * Neurologically instable with strokes, hemorrhages, increased intracranial pressures\n* Open wounds or surgical incisions\n\n  * Tenuous closed wounds requiring immobilization or bending restrictions\n  * Open wounds that are either packed\u002Fdressed or dressed with a wound vacuum\n  * Surgical wounds that are draining fluid or purulence\n* Vulnerable populations\n\n  * Incarcerated individuals\n* Patients without access to a mobile phone with iOS capability",{"count":21,"type":22},[25],"This study aims to evaluate the effectiveness of a mobile application in improving postoperative rehabilitation outcomes among patients undergoing orthopedic surgery.",[679,680,296,28],"Spine Degeneration","Hip Arthritis","2025-08-29",{"date":683,"type":48},"2025-09-02",{"date":685,"type":48},"2025-07-21",{"date":82,"type":22},{"name":688,"class":55},"Yale University"]